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ABSTRACT 
Objective: We aimed to determine the association between autoantibodies against 
apolipoprotein A-1 (anti-apoA-1 IgG) and prevalent cardiovascular (CV) disease (CVD) as well 
as markers of CV risk in the general population.  
Methods: Cross-sectional data were obtained from 6649 subjects (age 52.6±10.7 years, 47.4% 
male) of the population-based CoLaus study. CVD was defined as myocardial infarction, angina 
pectoris, percutaneous revascularization or bypass grafting for ischemic heart disease stroke or 
transient ischemic attack, and was assessed according to standardized medical records. Anti-
apoA-1 IgG and biological markers were measured by ELISA and conventional automated 
techniques, respectively. 
Results: Prevalence of high anti-apoA-1 IgG in the general population was 19.9%. Presence of 
anti-apoA-1 IgG was significantly associated with CVD [odds ratio 1.34, 95% confidence interval 
(1.05–1.70), p=0.018], independently of established CV risk factors (CVRFs) including age, sex, 
hypertension, smoking, diabetes, low and high-density lipoprotein cholesterol levels. 
The n=455 (6.8%) study participants with a history of CVD (secondary prevention subgroup) 
presented higher median anti-ApoA-1 IgG values compared with subjects without CVD 
(p=0.029). Among patients in the secondary prevention subgroup, those with positive anti-apoA-
1 IgG levels had lower HDL (p=0.002) and magnesium (p=0.001) levels, but increased uric acid 
and high-sensitivity C-reactive protein levels (p=0.022, and p<0.001, respectively) compared to 
patients with negative anti-apoA-1 IgG levels. 
Conclusion: Anti-apoA-1 IgG levels are independently associated with CVD in the general 
population and also related to CV biomarkers in secondary prevention. These findings indicate 
that anti-apoA-1 IgG may represent a novel CVRF and need further study in prospective cohorts.  
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INTRODUCTION 
Despite considerable advances having been made in its prevention, diagnosis and treatment, 
cardiovascular disease (CVD) remains the leading cause of death in the Western world. Major 
discoveries in the pathophysiology of CVD over the last 30 years have shifted the long-standing 
paradigm that held CVD primarily as a lipid-related metabolism disorder, to the current view of 
an immune-mediated inflammatory disease, where humoral autoimmunity may play an important 
role. (1, 2)  
Different lines of evidence indicate that autoantibodies may represent a novel, independent 
cardiovascular risk factor (CVRF), (3-5) not only in their potential role as biomarkers for risk 
stratification but also as mediators of CVD, amenable to targeted therapeutic strategies. (6) 
Among autoantibodies possibly related to CVD, those directed against apolipoprotein A-1 (anti-
apoA-1 IgG), the major protein fraction of high-density lipoproteins (HDL), are of particular 
interest. During the last decade, numerous translational studies have examined the mechanisms 
underpinning the role of anti-apoA-1 IgG in inflammation (7, 8) and atherogenesis. (9-12) In 
addition, preliminary clinical studies have shown encouraging results regarding the association 
and prognostic value of anti-apoA-1 IgG for CVD in subjects with autoimmune diseases, (9-11, 
13, 14) subjects at high CV risk, (15-17) or in secondary prevention. (18-23)  
Nevertheless, the prevalence of anti-apoA-1 IgG and their association with CVD or markers of 
CV risk in the general population have not yet been examined. Therefore, the purpose of our 
current study was manifold: first, to investigate the prevalence and association of anti-ApoA-1 
IgG with CVD in the general population. The second objective was to study the possible 
association of anti-ApoA-1 IgG with both established and emergent CV markers, in the general 
and secondary prevention populations. The third objective was to investigate the possible 
connexion between anti-apoA-1 IgG and serum magnesium concentrations, as anti-ApoA-1 IgG 
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have shown to be associated with a higher basal heart rate after MI (23) through activation of L-
type calcium channels, (24, 25) tightly regulated by intracellular magnesium concentrations. (26) 
MATERIALS AND METHODS 
Study population and design 
We obtained cross-sectional clinical and biological data from the CoLaus study, a population-
based observational study investigating cardiovascular disease (CVD) and risk factors in a 
random sample of 6733 subjects, aged between 35 and 75 and living in the city of Lausanne, 
Switzerland. Recruitment began in June 2003 and ended in May 2006. All participants of the 
CoLaus study were eligible for participation in the current study and were included in the 
analysis. The study was approved by the Institutional Ethics Committee of the University of 
Lausanne and informed consent was obtained from all participants. A detailed description of the 
study design and sampling procedures has been reported elsewhere. (27) 
All participants attended the outpatient clinic of the University Hospital of Lausanne in the 
morning, after an overnight fast. Data were collected from each participant by trained field 
interviewers in a single visit lasting about 60 minutes.  
Blood pressure and heart rate were measured three consecutive times using an automated 
sphygmomanometer (Omron® HEM-907, Matsusaka, Japan) and the average of the last two 
measurements was used. Hypertension was defined as a systolic blood pressure (SBP) ≥ 140 
mmHg and/or a diastolic blood pressure (DBP) ≥ 90 mmHg and/or presence of anti-hypertensive 
treatment. Diabetes mellitus was defined as fasting plasma glucose ≥7.0 mmol/L and/or oral or 
insulin antidiabetic treatment. Body weight was measured in kilograms to the nearest 0.1 kg 
using a Seca® scale (Hamburg, Germany) and height was measured to the nearest 5 mm using 
a Seca® height gauge (Hamburg, Germany). Body mass index (BMI) was defined as 
weight/height2. Metabolic syndrome was identified according to the NCEP-ATP III criteria (28) in 
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subjects presenting with at least 3 of the following components: 1) SBP>130 mm Hg or DBP>85 
mm Hg or treatment; 2) waist size>88 cm if female or >102 cm if male; 3) HDL-C<1.30 mmol/L 
for women or <1.03 mmol/L for men; 4) TG>1.7 mmol/L or lipid-lowering drug treatment; and 5) 
glucose>5.6 mmol/L or antidiabetic drug treatment. Aggregate CV risk was assessed using the 
Systematic COronary Risk Evaluation (SCORE) algorithm. Autoimmune disease was defined as 
history of rheumatoid arthritis or systemic lupus erythematosus, independently of treatment 
status. 
Prevalent CVD was defined by the presence of myocardial infarction; angina pectoris; 
percutaneous revascularization or bypass grafting for ischemic heart disease; stroke or transient 
ischemic attack and assessed according to standardized medical records. (27) 
A venous blood sample (50 ml) and a spot urine sample were collected from each participant 
under fasting conditions. The analytical procedures and clinical assays used for determining 
serum and urine biological markers are available in Supplemental Table I. The urinary 
fractional excretion of magnesium was calculated according to the following formula (29): 
FeMg = (UMg x SCr) / (0.7 x SMg x UCr), 
where UMg= urinary magnesium (mmol/L), SCr= serum creatinine (μmol/L), SMg= serum 
magnesium (mmol/L) and UCr= urinary creatinine (μmol/L). Glomerular filtration rate (GFR) was 
estimated by the simplified Modification of Diet in Renal Disease (MDRD) prediction equation: 
GFR (ml/min/1.73 m2) = 186 × (SCr)-1.154 × (Age)-0.203 × (0.742 if female), 
where SCr= plasma creatinine concentration in mg/dL, and age= years. 
Assessment of autoantibodies against apolipoproteinA-1 
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Anti-apoA-1 IgG were measured as previously described, (20, 21) using the CoLaus study 
(2003-2006) serum aliquots that had been previously frozen and stored at -80 °C. Maxisorp 
plates (NuncTM, Denmark) were coated with purified, human-derived delipidated apolipoprotein 
A-1 (20 μg/ml; 50 μl/well) for 1h at 37°C. After being washed, all wells were blocked for 1h with 
2% bovine serum albumin (BSA) in a phosphate buffer solution (PBS) at 37°C. Patient samples 
were also added to a non-coated well to assess individual non-specific binding. After six washing 
cycles, a 50 μl/well of signal antibody (alkaline phosphatase-conjugated anti-human IgG; Sigma-
Aldrich, St Louis, MO), diluted 1:1000 in a PBS/BSA 2% solution, was added and incubated for 
1h at 37°C. After washing six more times, phosphatase substrate p-nitrophanylphosphate 
disodium (Sigma-Aldrich) dissolved in a diethanolamine buffer (pH 9.8) was added and 
incubated for 20 min at 37°C (Molecular DevicesTM Versa Max). Optical density (OD) was 
determined at 405 nm, and each sample was tested in duplicate. Corresponding non-specific 
binding was subtracted from mean OD for each sample. The specificity of detection was 
assessed using conventional saturation tests by Western blot analysis. (20, 21) 
Elevated levels of anti-apoA-1 IgG were set at an OD cut-off of OD>0.64, corresponding to the 
97.5th percentile of a reference population of 140 healthy blood donors. In order to limit the 
impact of inter-assay variation, we calculated an index consisting in the ratio between sample 
net absorbance and the positive control net absorbance x 100. The index value corresponding to 
the 97.5th percentile of the normal distribution was 37. Accordingly, to be considered as positive 
(presenting elevated anti-apoA-1 IgG levels), samples had to display both an absorbance value 
>0.64 OD and an index value ≥37. 
Sample size and power calculation 
Based on previous published studies on healthy blood donors (21) we assumed an expected 
prevalence of anti-apoA-1 IgG in healthy subjects devoid of CVD of 5-10%. Taking into account 
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the CVD rate in CoLaus (455 events or 6.8%) and a two-sided alpha of 5%, our study had 80% 
power to detect an odds ratio (OR) of anti-apoA-1 IgG for CVD at OR=1.51.  
Statistical analysis 
Univariate analysis of continuous variables was performed using the student’s t-test or the non-
parametric Mann-Whitney test to account for non-parametric distributions, and results were 
expressed as mean ± standard deviation (SD) or as median (interquartile range), as appropriate. 
Analysis of discrete variables was performed using chi-square test and results were expressed 
as number of participants and (percentage).  
Multivariate analysis was performed using logistic regression adjusting for age, sex, 
hypertension, diabetes, smoking, low-density (LDL) and high-density lipoprotein cholesterol 
(HDL). Results were expressed as OR and 95% confidence interval (CI). All analyses were 
performed using STATA 13.0 (Stata Corp, College Station, Texas, USA). A two-tailed p<0.05 
was considered statistically significant. 
RESULTS 
Association between anti-apoA-1 IgG and CVD, independently of established CVRF 
The flowchart and objectives of the study are summarized in Figure 1. N=6194 (93.2%) study 
participants were devoid of baseline CVD (primary prevention subgroup), while n=455 (6.8%) 
were in secondary prevention. The distribution of raw optical density (OD) values for anti-apoA-1 
IgG in the sample is illustrated in Supplemental Figure I.  
As described in Table 1, elevated levels of anti-apoA-1 IgG were present in 1323 out of 6649 
(19.9%) study subjects. In the general population, the prevalence of clinical CVRF did not differ 
between subjects with presence vs. absence of anti-apoA-1 IgG. The same observation was true 
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both in the primary and the secondary prevention subgroups. Furthermore, we did not find any 
significant difference in CV drugs rates depending on presence vs. absence of anti-apoA-1 IgG. 
Among study subjects, n=154 had a history of autoimmune disease (either rheumatoid arthritis 
or systemic lupus erythematosus). We observed no association between history of autoimmune 
disease and elevated levels of anti-apoA-1 IgG in the population (Table 1). 
Prevalence of CVD in the general population was significantly associated with presence vs 
absence of anti-ApoA-1 IgG (8.3% vs. 6.5% respectively, p=0.018). Indeed, patients with history 
of CVD had higher median OD values for anti-ApoA-1 IgG than subjects without (OD: 0.412, 
interquartile range (IQR): 0.273 – 0.661 vs. 0.395, IQR: 0.253 – 0.589, p=0.029).  
Translated into odds ratio, elevated levels of anti-ApoA-1 IgG were associated with a 1.3-fold 
increased risk for prevalent CVD; an association which remained unchanged after adjustment for 
established CVRFs, including age, sex, hypertension, diabetes, smoking, LDL and HDL 
cholesterol. Alternatively, there was a 15% risk increase for prevalent CVD per standard 
deviation increase in anti-apoA-1 IgG values, which was also independent of established CVRFs 
(Table 2). Finally, the association between presence of anti-apoA-1 IgG and CVD in the 
multivariate model remained unchanged after further adjusting for history of autoimmune 
disease as well as after excluding subjects with history of autoimmune disease (n=154) from the 
analysis. 
Association between anti-apoA-1 IgG levels and biological markers of CV risk  
Table 3 summarizes variations in biological markers of CV risk, according to presence or 
absence of anti-apoA-1 IgG. 
Subjects with elevated anti-ApoA-1 IgG levels tended to have lower serum levels of total 
cholesterol, HDL and magnesium than patients with low anti-apoA-1 IgG levels. No trends or 
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significant differences were observed for other lipid parameters, renal function, hs-CRP or uric 
acid between these two groups. Inverse and significant Spearman correlations were retrieved for 
anti-apoA-1 IgG and total cholesterol as well as anti-apoA-1 IgG and magnesium levels both in 
the general population (r=-0.05, p<0.001; r=-0.06, p<0.001, respectively) and in the primary 
prevention subgroup (r=-0.05, p<0.001; r=-0.05, p<0.001, respectively). 
In the secondary prevention subgroup, patients with elevated anti-apoA-1 IgG levels presented 
significantly lower HDL and magnesium values, but higher hs-CRP and uric acid values than 
patients with low anti-apoA-1 IgG levels (Table 3). Additionally, inverse significant Spearman 
correlations were observed between anti-apoA-1 IgG and HDL (r=-0.10, p=0.03) or anti-apoA-1 
IgG and magnesium levels (r=-0.19; p<0.001), while significant positive correlations were found 
between anti-apoA-1 IgG and hs-CRP levels (r=0.11, p=0.02). The correlation for anti-apoA-1 
IgG and uric acid levels was also positive (r=0.09; p=0.05). No other significant correlations were 
observed between anti-apoA-1 IgG levels and biological parameters (data not shown). Notably, 
the negative association between anti-apoA-1 IgG and HDL levels remained robust after 
adjusting for statin treatment. Furthermore, no overall difference in the fractional excretion of 
magnesium in urine was found between subjects with presence vs. absence of anti-apoA-1 IgG, 
either in the general population or in the primary or secondary prevention subgroups (data not 
shown).  
In a subgroup analysis performed specifically on coronary heart disease (CHD) patients (n=235), 
subjects with elevated anti-apoA-1 IgG levels were more likely to present with metabolic 
syndrome and a higher basal heart rate when compared to patients with low anti-apoA-1 IgG 
levels (Supplemental Table II). Elevated levels of anti-apoA-1 IgG were also associated with 
significantly lower HDL and magnesium levels (p=0.015, p=0.004 respectively), and increased 
triglyceride (p=0.01) and hs-CRP levels (p=0.005) (Supplemental Table III). 
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DISCUSSION 
The main finding of the present large-scale study is the novel association between anti-apoA-1 
IgG and CVD in a population-based sample, which is independent of established CVRF. Our 
results validate initial reports, which suggested that presence of these autoantibodies could be 
associated with prevalent CVD, (14, 18) as well as CV complications in rheumatoid arthritis 
patients (13) and in high CV risk populations. (19, 22, 23) 
Furthermore, in this study we confirm that the presence of elevated anti-apoA-1 IgG levels in 
secondary prevention patients is associated with a pro-inflammatory systemic profile, (7-9, 13, 
14, 22) as reflected by lower HDL concentrations, but higher hs-CRP and uric acid levels. While 
different studies previously reported anti-apoA-1 IgG presence being associated with a loss of 
anti-atherogenic properties of HDL in specific settings, (9-12) this study is the first to indicate that 
elevated anti-apoA-1 IgG levels are inversely associated with HDL levels in subjects with 
established CVD, and remain so independently of statin treatment. 
Because anti-apoA-1 IgG target the major protein component of HDL, the association between 
anti-apoA-1 IgG and lower HDL levels may be related to the clearance of immune anti-apoA-1 
IgG and HDL complexes by the reticular-endothelial system. In accordance with this hypothesis, 
human case reports (30) reported that patients with high anti-apoA-1 IgG levels entirely lacked 
mature HDL particles, suggesting decreased ability of pre-beta HDL to become lipidated. Along 
the same line, in a murine model of SLE, anti-apoA-1 IgG could lower HDL levels without 
affecting hepatic HDL biosynthesis, possibly by accelerating HDL clearance.(12) On the other 
hand, anti-apoA-1 IgG passive immunization in mice has not shown to impact HDL levels, 
despite otherwise marked effects on atherogenesis, myocardial necrosis and survival, (8, 20) 
leaving the question open as to whether a causal link between apoA-1 IgG and HDL levels does 
exist. Lastly, the presence of these antibodies may also contribute to loss of HDL function by 
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impairing ATP-binding cassette transporter A1 (ABCA1)-mediated cholesterol efflux or 
interfering with paraoxonase 1 (PON1) activity, although this assumption requires further 
experimental validation. (9-12)  
Association between anti-apoA-1 IgG levels and biological markers of CV risk  
The fact that patients with high anti-apoA-1 IgG levels had higher hs-CRP levels than patients 
without anti-apoA-1 IgG is in line with previous studies showing that elevated anti-apoA-1 IgG 
levels were associated with higher circulating levels of pro-inflammatory cytokines, including IL-
6, TNF- alpha, myeloperoxidase, hs-CRP and matrix-metalloproteinase 9. (7, 13, 17, 20, 22) 
Because endotoxin-free anti-apoA-1 IgG was shown to induce a dose-dependent production of 
IL-6 and other inflammatory cytokines by human macrophages in a TLR2/CD14 dependent 
manner, (7) a straightforward explanation for this association could be that the anti-apoA-1 IgG-
driven production of IL-6 by macrophages directly induces CRP production by hepatocytes, a 
phenomenon highly dependent on IL-6 stimulus. (31, 32) 
Another compelling finding of our study was that patients with high anti-apoA-1 IgG levels had 
significantly lower serum magnesium concentrations compared to patients with low anti-apoA-1 
IgG levels. Previous studies showed anti-apoA-1 IgG to elicit in vitro a sustained positive 
chronotropic response on cardiomyocytes through the activation of L-type calcium channels, (24, 
25) the activity of which is enhanced by intracellular magnesium deficiency. (26) Since 
magnesium depletion predisposes for cardiac arrhythmias and CHD, (33) this descriptive 
association could provide a model to support our previous observation that showed elevated 
anti-apoA-1 IgG levels after myocardial infarction to be associated with a higher basal heart rate, 
as assessed by Holter monitoring. (23) Interestingly, in the present study – apart from the 
difference in circulating concentrations of magnesium not previously assessed (23) – we found 
the same association between elevated anti-apoA-1 IgG levels and basal heart rate in the 
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subgroup of CHD patients. It is therefore plausible that the higher basal heart rate observed in 
CHD patients with elevated anti-apoA-1 IgG levels could be mediated by concomitant lower 
magnesium concentrations, or that these patients have increased chronotropic susceptibility to 
relative hypomagnesaemia. Since the fractional excretion of magnesium did not differ between 
subjects with high vs. low anti-apoA-1 IgG levels, one can reasonably exclude urinary 
magnesium wasting as the cause of this finding.  
Strengths and limitations 
The strength of our study lies in its unbiased, community-based approach that enabled us to 
confirm that elevated anti-apoA-1 IgG are independently associated with CVD in a large and 
extensively characterized sample of the general population. 
There are several limitations to this study. First, owing to the cross-sectional nature of the data, 
a causal relationship between anti-ApoA-1 IgG and CVD cannot be firmly established. This 
hypothesis is currently being tested in an ongoing longitudinal study aiming at exploring the 
prognostic value of anti-ApoA-1 IgG in the general population. 
Secondly, we did not measure apoA-1 levels nor did we assess the possible qualitative changes 
in HDL, such as PON1 activity, reverse cholesterol efflux capacity or HDL anti-inflammatory 
properties. As apoA-1 is largely responsible for reverse cholesterol transport and stabilization of 
PON1, (34) it is plausible that anti-apoA-1 IgG could decrease apoA-1 levels, rendering the 
protein less able to promote cholesterol efflux and thereby manifest its anti-atherogenic effects. 
We assume that both apoA-1 levels and HDL functional properties would be altered in anti-
apoA-1 IgG positive patients, as reported earlier; (11) however, we did not collect data to 
challenge this hypothesis. 
16 
 
Thirdly, it remains elusive as to whether elevated anti-apoA-1 IgG levels are associated with 
susceptibility to infections. Previous studies reported that polyclonal human anti-apoA-1 IgG 
response is focused against epitopes present on the C-terminal part of apoA-1. (35, 36) Since 
the latter shares structural homologies with TLR2, (7) it is suggested that pathogen molecular 
mimicry may be the underlying mechanism for the deleterious properties of these 
autoantibodies. The design of this study did not allow for the exploration of association between 
the existence of anti-apoA-1 IgG and previous exposure to specific pathogens. 
CONCLUSION 
The present study confirms that elevated anti-apoA-1 IgG levels are independently associated 
with CVD in the general population, while also being associated with CV biomarkers in patients 
with a history of CVD. Prospective studies are needed to evaluate the prognostic value of anti-
apoA-1 IgG as a biomarker for CVD in the general population as well as to investigate the 
possible therapeutic value of developing immune therapies directed against anti-apoA-1 IgG.  
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LEGENDS TO FIGURES AND TABLES 
Figure 1: Study flowchart and endpoints. 
Anti-apoA-1 IgG, Autoantibodies against Apolipoprotein A-1; CVD, Cardiovascular Disease; CV, 
Cardiovascular 
Table 1: Continuous data are expressed as mean ± standard deviation or median (interquartile 
range) according to the variable distribution. Categorical data are expressed as number of 
participants and (percentage). Statistical analysis by chi-square for categorical variables and 
Mann-Whitney U test for continuous variables. Anti-apoA-1 IgG, Autoantibodies against 
Apolipoprotein A-1; BP; blood pressure; CVD, cardiovascular disease; SCORE, Systematic 
Coronary Risk Evaluation. The primary and secondary prevention subgroups are issued from 
the general study population. 
Table 2: Results are expressed as odds ratio (95% confidence interval). Statistical analysis was 
performed by multivariate logistic regression. The adjusted model was adjusted for age, sex, 
hypertension, diabetes, smoking, HDL cholesterol and LDL cholesterol. Anti-apoA-1 IgG, 
Autoantibodies against Apolipoprotein A-1; OD, optical density  
* Subjects with positive anti-ApoA-1 (n=1323) were divided in tertiles of increasing titers: 1st 
tertile (0.64≤OD<0.77), 2nd tertile (0.77≤OD<0.98) and 3rd tertile (OD>0.98). 
Table 3: Data are expressed as mean ± standard deviation or median (interquartile range) 
according to the variable distribution. Statistical analysis was performed by Mann-Whitney test. 
Anti-apoA-1 IgG, Autoantibodies against Apolipoprotein A-1; LDL, low density lipoprotein; HDL, 
high density lipoprotein; eGFR, Estimated Glomerular Filtration Rate (MDRD equation); CVD, 
Cardio Vascular Disease; hs-CRP, high-sensitivity C-Reactive Protein. The primary and 
secondary prevention subgroups are issued from the general study population. 
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Table 1: Clinical characteristics of the sample according to anti-apoA-1 IgG status: a) general population, b) primary prevention 
and c) secondary prevention subgroups. 
 General population                
(n=6649) 
Primary prevention subgroup 
(n=6194) 
Secondary prevention 
subgroup (n=455) 
Anti-apoA-1 IgG Negative Positive p-
value 
Negative Positive p-
value 
Negative Positive p-
value 
Sample size, n (%) 5326 (80.1) 1323 (19.9)  4981 (80.4) 1213 (19.6)  345 (75.8) 110 (24.2)  
Age, years 52.7 ± 10.8 52.3 ± 10.7 0.201 52.1 ± 10.6 51.6 ± 10.6 0.130 61.6 ± 9.2 60.0 ± 9.4 0.099 
Male sex, n (%) 2527 (47.5) 626 (47.3) 0.933 2336 (46.9) 556 (45.8) 0.506 191 (55.4) 70 (63.6) 0.127 
CVD, n (%) 345 (6.5) 110 (8.3) 0.018 .0 (0.0) 0 (0.0). . 345 (100.0) 110 (0.0) . 
Hypertension, n (%) 1851 (34.8) 456 (34.5) 0.844 1619 (32.5) 382 (31.5) 0.499 232 (67.3) 74 (67.3) 0.996 
Diabetes, n (%) 351 (6.6) 81 (6.1) 0.537 294 (5.9) 61 (5.0) 0.240 57 (16.5) 20 (18.2) 0.686 
Metabolic syndrome, n 
(%) 
1196 (22.5) 309 (23.4) 0.484 956 (19.6) 257 (19.5) 0.907 58 (21.5) 52 (28.1) 0.105 
Current smoking, n (%) 1422 (26.7) 358 (27.1) 0.791 1347 (27.0) 326 (26.9) 0.906 75 (21.7) 32 (29.1) 0.113 
Autoimmune disease 116 (2.2) 38 (2.9) 0.133 105 (2.1) 32 (2.6) 0.260 11 (3.2) 6 (5.5) 0.275 
Heart rate, bpm 68.0 ± 9.7 68.1 ± 10.3 0.656 68.1 ± 9.6 68.2 ± 10.3 0.920 66.5 ± 10.6 68.0 ± 9.6 0.170 
Systolic BP, mmHg 128 ± 18 128 ± 18 0.471 128 ± 18 127 ± 18 0.402 136 ± 120 136 ± 20 0.972 
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Body mass index, kg/m2 25.8 ± 4.5 25.8 ± 4.7 0.853 25.7 ± 4.4 25.6 ± 4.6 0.813 27.6 ± 5.0 28.1 ± 5.2 0.396 
CV risk (SCORE) 0.6 (0.2 – 
2.2) 
0.6 (0.2 – 
2.1) 
0.165 0.6 (0.2 – 
1.9) 
0.5 (0.2 – 
1.8) 
0.059 3.1 (0.9 – 
6.6) 
2.8 (0.9 – 
5.8) 
0.546 
CV drugs          
Aspirine 855 (16.0) 191 (14.4) 0.148 677 (13.6) 140 (11.5) 0.058 178 (51.6) 51 (46.4) 0.339 
Statins 581 (10.9) 123 (9.30) 0.088 432 (8.7) 81 (6.7) 0.024 149 (43.2) 42 (38.2) 0.354 
Beta blockers 284 (5.3) 81 (6.1) 0.259 198 (4.0) 48 (4.0) 0.977 86 (24.9) 33 (30.0) 0.292 
Calcium channel 
blockers 
161 (3.0) 43 (3.2) 0.668 113 (2.3) 30 (2.5) 0.670 48 (13.9) 13 (11.8) 0.574 
IEC/ARB 408 (7.7) 88 (6.7) 0.211 339 (6.8) 70 (5.8) 0.193 69 (20.0) 18 (16.4) 0.398 
Diuretics 120 (2.2) 22 (1.7) 0.184 98 (2.0) 17 (1.4) 0.190 22 (6.4) 5 (4.6) 0.479 
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Table 2: Odds ratio of anti-apoA-1 IgG for cardiovascular disease in unadjusted and adjusted models. 
 Unadjusted model p-value Adjusted model p-value 
 OR (95% CI)  OR (95% CI)  
Positive anti-ApoA-1 IgG 
(OD≥0.64) vs negative 
(OD<0.64)  
1.31 (1.05 – 1.64) 0.018 1.34 (1.05 – 1.70) 0.018 
1SD change in OD levels 1.15 (1.05 – 1.25) 0.003 1.18 (1.07 – 1.30) 0.001 
Anti-ApoA-1 IgG levels *     
Negative (OD<0.64) 1 (ref.)  1 (ref.)  
1st tertile (0.64≤OD<0.77) 1.02 (0.69 – 1.50) 0.936 1.15 (0.76 – 1.74) 0.507 
2nd tertile (0.77≤OD<0.98) 1.24 (0.87 – 1.79) 0.236 1.14 (0.76 – 1.70) 0.529 
3rd tertile (OD≥0.98) 1.68 (1.22 – 2.33) 0.002 1.71 (1.21 – 2.42) 0.002 
P-value for linear trend 0.002  0.008  
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Table 3: Biological characteristics of the sample according to anti-apoA-1 IgG status: a) general population, b) primary 
prevention and c) secondary prevention subgroups. 
 General population                 
(n=6649) 
Primary prevention subgroup 
(n=6194) 
Secondary prevention subgroup 
(n=455) 
Anti-apoA-1 IgG Negative Positive p-
value 
Negative Positive p-value Negative Positive p-
value 
Sample size, n (%) 5326 
(80.1) 
1323 
(19.9) 
 4981 
(80.4) 
1213 
(19.6) 
 345 (75.8) 110 (24.2)  
Lipids (mmol/L)          
Total cholesterol 5.59 ± 1.04 5.53 ± 1.05 0.067 5.60 ± 1.03 5.55 ± 1.03 0.064 5.32 ± 1.04 5.35 ± 1.20 0.854 
LDL cholesterol 3.34 ± 0.92 3.30 ± 0.92 0.168 3.35 ± 0.91 3.31 ± 0.91 0.117 3.13 ± 0.92 3.20 ± 1.01 0.449 
HDL cholesterol 1.63 ± 0.43 1.62 ± 0.46 0.052 1.64 ± 0.43 1.63 ± 0.46 0.351 1.53 ± 0.42 1.40 ± 0.36 0.002 
Triglycerides 1.10 
(0.8–1.6) 
1.10 
(0.8–1.6) 
0.082 1.1 
(0.8–1.6) 
1.1 
(0.8–1.5) 
0.150 1.3 
(0.9–1.8) 
1.4 
(1 – 2.1) 
0.083 
Renal function          
eGFR, mL/min/1.73 
m2 
77.8 
(69–88) 
78.3 
(68–89) 
0.312 77.9 
(69–88) 
78.4 
(69–89) 
0.287 76.2 
(66–86) 
75.7 
(66–91) 
0.877 
Serum ions (mmol/L)          
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Magnesium 0.85 ± 0.07 0.84 ± 0.07 <0.001 0.85 ± 0.07 0.84 ± 0.07 <0.001 0.84 ± 0.07 0.81 ± 0.07 0.001 
Calcium 2.29 ± 0.09 2.28 ± 0.09 0.103 2.28 ± 0.09 2.28 ± 0.09 0.120 2.31 ± 0.09 2.30 ± 0.10 0.413 
Surrogate markers of 
CVD 
         
Uric acid, µmol/L 306 
(251–365) 
302 
(249–365) 
0.689 304 
(249–363) 
299 
(247–358) 
0.173 335 
(274–394) 
351 
(299–415) 
0.022 
Homocysteine, 
µmol/L 
9.5 
(7.9–11.7) 
9.5 
(7.8–11.6) 
0.596 9.5 
(7.9–11.5) 
9.4 
(7.7–11.4) 
0.198 10.2 
(8.6–13.0) 
11.3 
(9.0–14.4) 
0.078 
hs-CRP, mg/L 1.3 
(0.6–2.7) 
1.2 
(0.6–2.8) 
0.588 1.3 
(0.6–2.7) 
1.1 
(0.6–2.5) 
0.082 1.6 
(0.7–3.0) 
2.1 
(1.2–5.0) 
<0.001 
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Extra Table 
1. What is known on this topic 
• Numerous translational studies have established the role of autoantibodies against apolipoprotein A-1 in inflammation and 
atherogenesis. 
• Small-scale clinical studies have shown promising results regarding the association and prognostic value of autoantibodies against 
apolipoprotein A-1 for cardiovascular disease in subjects with autoimmune diseases, subjects at high CV risk or following 
myocardial infarction. 
2. What this paper adds 
• This is the first study to demonstrate that autoantibodies against apolipoprotein A-1 are significantly associated with prevalent 
cardiovascular disease in the general population, independently of established cardiovascular risk factors.  
• Our results suggest that autoantibodies against apolipoprotein A-1 may prove useful as a novel biomarker as well as a potential 
target for specific immune modulation strategies for cardiovascular disease. 
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Supplemental Figure I: Distribution of anti-apoA-1 IgG levels (in optical density) in the 
CoLaus study population 
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Supplemental Table I: Clinical assays used to evaluate biological markers in the CoLaus study. 
Markers Type of assay Maximum inter 
and intra-batch 
CVs 
 Manufacturer 
Lipids (mmol/L)    
Total Cholesterol CHOD-PAP method 1.6% – 1.7% Cobas 8000, 
Roche Diagnostics, 
CH 
LDL cholesterol Friedewald formula, only if triglycerides <4.6 mmol/l   
HDL cholesterol CHOD-PAP + PEG + cyclodextrin method 3.6% – 0.9% Cobas 8000, 
Roche Diagnostics, 
CH 
Triglycerides GPO-PAP method 2.9% – 1.5% Cobas 8000, 
Roche Diagnostics, 
CH 
Renal function    
Creatinine, μmol/L Jaffe kinetic compensated method 2.9% – 0.7% Cobas 8000, 
Roche Diagnostics, 
CH 
Serum ions (mmol/L)    
Magnesium Colorimetric Assay (Xylidyl Blue-I method) 2.9% – 0.8% Cobas 8000, 
Roche Diagnostics, 
CH 
Calcium Colorimetric Assay (O-cresolphtalein method) 2.1% – 1.5% Cobas 8000, 
Roche Diagnostics, 
CH 
Surrogate markers of CVD    
Uric acid, μmol/L Uricase-PAP method 1.0% – 0.5% Cobas 8000, 
Roche Diagnostics, 
CH 
Homocysteine, μmol/L High pressure liquid chromatography following ammonium 
7-fluorobenzo-2-oxa-1, 3-diazole -4-sulphonate (SBD-F) 
derivatisation 
3.1% – 2.9% Agilent 1100 
apparatus 
hs-CRP, mg/L Latex-enhanced turbidimetric immunoassay method 4.6% – 1.3% Cobas 8000, 
Roche Diagnostics, 
CH 
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CV, coefficient of variation; CHOD, cholesterol oxidase; PAP, phenol aminophenazone; PEG, polyethylene glycol; GPO, glycerol-3-
phosphate oxidase; LDL, low density lipoprotein; HDL, high density lipoprotein; hs-CRP, high-sensitivity C-reactive protein 
 
Urine    
Creatinine, μmol/L Jaffe kinetic compensated method 2.2% – 2.1% Cobas 8000, 
Roche Diagnostics, 
CH 
Magnesium, mmol/L Colorimetric Assay (Xylidyl Blue-I method) 2.1% – 1.4% Cobas 8000, 
Roche Diagnostics, 
CH 
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Supplemental Table II: Clinical characteristics of subjects with established coronary heart disease according to anti-
apoA-1 IgG status. 
 Subjects with established CHD (n=235) 
Anti-apoA-1 IgG Negative Positive p-value 
Sample size, n (%) 183 (77.9) 52 (22.1)  
Age, years 63.1 ± 8.8 61.0 ± 8.6 0.084 
Male sex, n (%) 127 (69.4) 41 (78.9) 0.183 
Hypertension, n (%) 137 (74.9) 38 (73.1) 0.794 
Diabetes, n (%) 34 (18.6) 13 (25.0) 0.307 
Metabolic syndrome, n (%) 78 (42.6) 31 (59.6) 0.030 
Current smoking, n (%) 44 (24.0) 14 (26.9) 0.671 
Heart rate, bpm 64.2 ± 10.8 66.9 ± 9.36 0.042 
Systolic BP, mmHg 136.7 ± 17.8 137.1 ± 22.3 0.797 
Body mass index, kg/m2 28.0 ± 4.8 29.2 ± 4.4 0.067 
 
Data are expressed as mean ± standard deviation or number of participants and (percentage). Statistical analysis performed by 
chi-square for categorical variables and Mann-Whitney U test for continuous variables. Anti-apoA-1 IgG, Autoantibodies against 
Apolipoprotein A-1; BP, blood pressure  
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Supplemental Table III: Biological characteristics of subjects with established coronary heart disease according to 
anti-apoA-1 IgG status. 
 Subjects with established CHD (n=235) 
Anti-apoA-1 IgG Negative Positive p-value 
Sample size, n (%) 183 (77.9) 52 (22.1)  
Lipids (mmol/L) 
Total cholesterol 5.06 ± 1.00 5.21 ± 1.05 0.159 
LDL cholesterol 2.94 ± 0.88 3.09 ± 0.95 0.154 
HDL cholesterol 1.43 ± 0.37 1.30 ± 0.29 0.015 
Triglycerides 1.3 (1.0 – 1.9) 1.7 (1.1 – 2.3) 0.010 
Serum ions (mmol/L) 
Magnesium 0.85 ± 0.07 0.81 ± 0.07 0.004 
Calcium 2.31 ± 0.09 2.31 ± 0.11 0.531 
Renal function 
eGFR, ml/min/1.73 m2 75.7 (65.4 – 86.2) 75.7 (67.9 – 91.9) 0.593 
Surrogate markers of CVD 
Uric acid, µmol/L 355 (299 – 417) 369 (331 – 420) 0.294 
Homocysteine, µmol/L 11 (8.8 – 14.1) 12.6 (9.4 – 14.4) 0.127 
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hs- CRP, mg/L 1.6 (0.9 – 3) 2.3 (1.3 – 5.5) 0.005 
 
Data are expressed as mean ± standard deviation or median (inter quartile range) according to the variable distribution. 
Statistical analysis was performed by Mann-Whitney test. Anti-apoA-1 IgG, Autoantibodies against Apolipoprotein A-1; 
LDL, low density lipoprotein; HDL, high density lipoprotein; eGFR, estimated glomerular filtration rate (MDRD equation); 
CVD, cardiovascular disease; hs-CRP, high-sensitivity C-reactive protein 
